Clinical trials: Non-communicable Diseases
Hepatitis C
A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects
This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals
- Trial name
- NCT02760758
- Testing
- CDI-31244
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.
Sepsis, Shock, Septic
Sepsis Assessment in Belgian Emergency Rooms
To validate the use of the Heparin Binding Protein (HBP) concentration to assist in the evaluation of patients admitting to the emergency department with suspected infection.
- Conditions
- Sepsis, Shock, Septic, Severe Sepsis
- Trial name
- SABER (NCT02424721)
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Axis Shield Diagnostics Ltd
Infection
LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection
The primary objective is: to assess the microbiological success of the combination of levofloxacin and rifampicin, administered for 32 to 37 days, as oral replacement therapy of an empirical antibiotic therapy of a maximum of 5…
- Trial name
- NCT00906048
- Testing
- Levofloxacin (HR355) and Rifampicin Therapy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Sanofi
HIV Infection
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum.
- Trial name
- NCT00246610
- Testing
- Nelfinavir mesylate, 625 mg
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Pfizer
Hepatitis B Infection
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.
- Trial name
- NCT03519113
- Testing
- GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Green Cross Corporation